MARKET

ANL

ANL

Adlai Nortye Ltd.
NASDAQ
13.26
+0.18
+1.34%
Opening 12:40 08/12 EDT
OPEN
13.08
PREV CLOSE
13.08
HIGH
13.40
LOW
12.48
VOLUME
64.77K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
0.8786
MARKET CAP
853.59M
P/E (TTM)
-11.9296
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANL last week (0803-0807)?
Weekly Report · 2d ago
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated
TipRanks · 08/03 16:55
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial
TipRanks · 08/03 12:29
Adlai Nortye submits clinical trial notification to Australia TGA for AN4035
TipRanks · 08/03 11:50
Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
Benzinga · 08/03 11:04
Weekly Report: what happened at ANL last week (0727-0731)?
Weekly Report · 08/03 09:20
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Barchart · 08/03 06:00
Adlai Nortye: AN9025 Still Needs Human Validation
Seeking Alpha · 07/31 15:13
More
About ANL
Adlai Nortye Ltd. is a global clinical-stage biotechnology company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor and AN4035, a Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5).

Webull offers Adlai Nortye Ltd (ADR) stock information, including NASDAQ: ANL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANL stock methods without spending real money on the virtual paper trading platform.